Long-Term Response and Postsurgical Complete Remissions After Treatment With Sunitinib Malate, an Oral Multitargeted Receptor Tyrosine Kinase Inhibitor, in Patients With Metastatic Renal Cell Carcinoma

By Ayllon Jorge   Beuselinck Benoit   Morel Alexandre   Barrascout Eduardo   Medioni Jacques   Scotte Florian   Oudard Stééphane  

Cancer Investigation, Vol. 29, Iss. 4, 2011-04 ,pp. : 282-285

Informa Healthcare

Access to resources Recommend Favorite

Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

By Yasuda Yosuke   Saito Kazutaka   Yuasa Takeshi   Kitsukawa Shinichi   Urakami Shinji   Yamamoto Shinya   Yonese Junji   Takahashi Shunji   Fukui Iwao  

International Journal of Clinical Oncology, Vol. 18, Iss. 5, 2013-10 ,pp. : 884-889

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan

By          

Molecular and Clinical Oncology, Vol. 3, Iss. 3, 2015-01 ,pp. : 601-606

Science Publishers

Access to resources Recommend Favorite

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

By Hayashi Hidetoshi   Nakagawa Kazuhiko  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 441-443

Future Medicine

Access to resources Recommend Favorite

Sunitinib for metastatic renal cell carcinoma

By Mukherji Deborah   Larkin James   Pickering Lisa  

Future Oncology, Vol. 6, Iss. 9, 2010-09 ,pp. : 1377-1385

Future Medicine

Access to resources Recommend Favorite